Showing results (531-540 of 712) with videos related to
Sort By:
Pageof 72
Advanced Materials (Deerfield Beach, Fla.)|June 25, 2020
Bioactive-Tissue-Derived Nanocomposite Hydrogel for Permanent Arterial Embolization and Enhanced Vascular HealingJingjie Hu, Izzet Altun, Zefu Zhang, et al.Current Oncology Reports|May 28, 2025
Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 InhibitorsPhilip D Tracy, Emily Bopp, Emily Milner, et al.Science (New York, N.Y.)|January 13, 2022
Bacterial gasdermins reveal an ancient mechanism of cell deathAlex G Johnson, Tanita Wein, Megan L Mayer, et al.Hypertension (Dallas, Tex. : 1979)|April 13, 2011
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humansErica L Mayer, Susan M Dallabrida, Maria A Rupnick, et al.Cancer Chemotherapy and Pharmacology|March 19, 2015
Dose selection of siltuximab for multicentric Castleman's diseaseChristina L Mayer, Lanyi Xie, Rajesh Bandekar, et al.Human Reproduction (Oxford, England)|April 8, 2016
Diet-induced obesity impairs endometrial stromal cell decidualization: a potential role for impaired autophagyJulie S Rhee, Jessica L Saben, Allyson L Mayer, et al.International Journal of Environmental Health Research|March 2, 2017
Saharan dust and the impact on adult and elderly allergic patients: the effect of threshold values in the northern sector of Gran Canaria, SpainInmaculada Menéndez, Edward Derbyshire, Teresa Carrillo, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 9, 2005
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group studyRudolph M Navari, Lawrence H Einhorn, Steven D Passik, et al.Macromolecular Bioscience|May 19, 2010
Accounting for solvent signal offsets in the analysis of interferometric sedimentation velocity dataHuaying Zhao, Patrick H Brown, Andrea Balbo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancerErica L Mayer, Jean-Francois Baurain, Joseph Sparano, et al.Pageof 72